Trade Exelixis, Inc. - EXEL CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.12 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 22.88 |
| Open | 22.76 |
| 1-Year Change | 15.36% |
| Day's Range | 22.76 - 23.4 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 22.89 | 0.73 | 3.29% | 22.16 | 22.94 | 22.12 |
| Jul 24, 2024 | 22.29 | 0.13 | 0.59% | 22.16 | 22.48 | 22.16 |
| Jul 23, 2024 | 22.40 | 0.10 | 0.45% | 22.30 | 22.69 | 22.26 |
| Jul 22, 2024 | 22.53 | 0.08 | 0.36% | 22.45 | 22.69 | 22.38 |
| Jul 19, 2024 | 22.53 | 0.13 | 0.58% | 22.40 | 22.69 | 22.40 |
| Jul 18, 2024 | 22.45 | 0.17 | 0.76% | 22.28 | 22.63 | 22.28 |
| Jul 17, 2024 | 22.39 | -0.17 | -0.75% | 22.56 | 22.80 | 22.30 |
| Jul 16, 2024 | 22.71 | 0.24 | 1.07% | 22.47 | 22.88 | 22.37 |
| Jul 15, 2024 | 22.43 | 0.26 | 1.17% | 22.17 | 22.60 | 22.17 |
| Jul 12, 2024 | 22.35 | 0.09 | 0.40% | 22.26 | 22.69 | 22.26 |
| Jul 11, 2024 | 22.47 | 0.42 | 1.90% | 22.05 | 22.67 | 22.00 |
| Jul 10, 2024 | 21.98 | -0.12 | -0.54% | 22.10 | 22.25 | 21.94 |
| Jul 9, 2024 | 22.08 | 0.16 | 0.73% | 21.92 | 22.09 | 21.80 |
| Jul 8, 2024 | 22.04 | 0.08 | 0.36% | 21.96 | 22.34 | 21.96 |
| Jul 5, 2024 | 22.04 | 0.19 | 0.87% | 21.85 | 22.11 | 21.77 |
| Jul 3, 2024 | 21.89 | -0.16 | -0.73% | 22.05 | 22.14 | 21.77 |
| Jul 2, 2024 | 22.10 | 0.13 | 0.59% | 21.97 | 22.20 | 21.97 |
| Jul 1, 2024 | 22.18 | -0.13 | -0.58% | 22.31 | 22.66 | 22.07 |
| Jun 28, 2024 | 22.41 | 0.15 | 0.67% | 22.26 | 22.52 | 22.26 |
| Jun 27, 2024 | 22.49 | 0.14 | 0.63% | 22.35 | 22.53 | 22.24 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Exelixis Company profile
Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.| Industry: | Bio Therapeutic Drugs |
1851 Harbor Bay Parkway
ALAMEDA
CALIFORNIA 94502
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com